Opko Halts Phase III Study of siRNA Treatment for AMD on Poor Preliminary Data

Although the future of the drug is unclear, an Opko executive said that the firm remains committed to its portfolio of VEGF-targeting siRNAs.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories